SLC5A2 and chronic kidney disease: Dapagliflozin, an SGLT2 inhibitor, reduces the risk of kidney failure and cardiovascular death/HF hospitalization and prolongs survival in people with CKD, regardless of the presence of type 2 diabetes [50].